What is the price-to-earnings ratio of Medincell?
The price-earnings ratio of Medincell is currently 50.97.
Medincell P/S 2024
Medincell P/S
50.97
Ticker
MEDCL.PA
ISIN
FR0004065605
WKN
A2N6VA
As of Sep 21, 2024, Medincell's P/S ratio stood at 50.97, a 202.67% change from the 16.84 P/S ratio recorded in the previous year.
The Medincell P/S history
Medincell Aktienanalyse
What does Medincell do?
Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Medincell's P/S Ratio
Medincell's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Medincell's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Medincell's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Medincell’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Medincell stock
How has the price-earnings ratio of Medincell changed compared to last year?
The price-to-earnings ratio of Medincell has increased by 202.67% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Medincell high compared to other companies?
Yes, the price-to-earnings ratio of Medincell is high compared to other companies.
How does an increase in the price-earnings ratio of Medincell affect the company?
An increase in the price-earnings ratio of Medincell would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Medincell affect the company?
A decrease in the price-earnings ratio of Medincell would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Medincell?
Some factors that influence the price-earnings ratio of Medincell are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Medincell pay?
Over the past 12 months, Medincell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medincell is expected to pay a dividend of 0 EUR.
What is the dividend yield of Medincell?
The current dividend yield of Medincell is .
When does Medincell pay dividends?
Medincell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Medincell?
Medincell paid dividends every year for the past 0 years.
What is the dividend of Medincell?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Medincell located?
Medincell is assigned to the 'Health' sector.
Wann musste ich die Aktien von Medincell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Medincell from 9/21/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.
When did Medincell pay the last dividend?
The last dividend was paid out on 9/21/2024.
What was the dividend of Medincell in the year 2023?
In the year 2023, Medincell distributed 0 EUR as dividends.
In which currency does Medincell pay out the dividend?
The dividends of Medincell are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Medincell stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Medincell
Our stock analysis for Medincell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medincell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
